Application of a kind of prothrombin mutant protein and its coding nucleic acid
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
- Publication Date
- 2021-05-11
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
Technical field
[0001] The invention belongs to the field of bleeding treatment, and in particular, the present invention relates to a prothrombin mutant protein and its encoding nucleic acid.Background technique
[0002] Coagulation factor defects or other human coagulation dysfunction can result in hemorrhagic diseases, in which hemorrhagic diseases (A -1 / B) due to blood-bleeding disease caused by coagulation factor VIII / IX (FVII / FIX) defects , Severe patients' coagulation factor VIII / IX activity is often less than 1% of normal, often spontaneous bleeding results in muscle hematoma or articulation. Infusion factor VIII / IX preparation (currently usually a thirty-expression of thromboplane VIII / IX protein) supplemented with the patient's body is the only effective treatment, but frequent administration is required. Genetic therapy is currently in the treatment of clinical trials, and introduces normal coagulation factor VIII / IX gene into patients, thereby achieving improving...